Form 4: Olema Pharmaceuticals Director Cyrus Harmon Sells 5,000 Shares
SEC Form 4 Filing
Director Cyrus Harmon of Olema Pharmaceuticals sold 5,000 shares of common stock at an average price of $12.26, according to a Form 4 filing with the SEC.
Summary
- On July 11, 2024, Cyrus Harmon, a director of Olema Pharmaceuticals, sold 5,000 shares of common stock.
- The sale was executed at a weighted average price of $12.26 per share, with individual prices ranging from $12.23 to $12.33.
- The transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on May 16, 2023.
- Following the transaction, Harmon directly owns 756,283 shares and indirectly owns 122,028 shares through Harmon Family Investors LLC.
- Shane Kovacs, Attorney-in-Fact, signed the Form 4 on July 12, 2024.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a stock sale by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider trading activity. It provides transparency to investors regarding the transactions of company insiders.
Stakeholder Impact
- The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 trading plan mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| May 16, 2023 | Date of adoption of the 10b5-1 trading plan. |
| July 11, 2024 | Date of the stock sale transaction. |
| July 12, 2024 | Date the Form 4 was signed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.